MovDisordV3, Main, Exploration, bibRecord, 004963

Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease

Identifieur interne : 004963 ( Main/Exploration ); précédent : 004962; suivant : 004964

Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease

Auteurs : Theresa A. Zesiewicz [États-Unis] ; Mohammed Helal [États-Unis] ; Robert A. Hauser [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2000-03.

RBID : ISTEX:3DECA42D5307E6BAA4476E1058D97F6523C1220B

Descripteurs français

Pascal (Inist)
- Adulte, Chimiothérapie, Complication, Fonction sexuelle, Impuissance, Mâle, Parkinson maladie, Sildénafil, Toxicité, Traitement.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Aged, Chemotherapy, Complication, Dose-Response Relationship, Drug, Erectile Dysfunction (drug therapy), Erectile dysfunction, Humans, Impotence, Libido (drug effects), Male, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Penile Erection (drug effects), Phosphodiesterase Inhibitors (administration & dosage), Phosphodiesterase Inhibitors (adverse effects), Pilot Projects, Piperazines (administration & dosage), Piperazines (adverse effects), Purines, Sexual function, Sildenafil, Sildenafil citrate, Sulfones, Toxicity, Treatment, Treatment Outcome, Viagra.
MESH :
- chemical , administration & dosage : Phosphodiesterase Inhibitors, Piperazines.
- chemical , adverse effects : Phosphodiesterase Inhibitors, Piperazines.
- drug effects : Libido, Neurologic Examination, Penile Erection.
- drug therapy : Erectile Dysfunction, Parkinson Disease.
- Aged, Dose-Response Relationship, Drug, Humans, Male, Pilot Projects, Purines, Sulfones, Treatment Outcome.

Abstract

Sildenafil citrate (Viagra) is a phosphodiesterase type V inhibitor used to treat erectile dysfunction. Ten men with idiopathic Parkinson's disease (PD) and erectile dysfunction were prescribed 50–100 mg sildenafil citrate to use in eight sexual encounters over a 2‐month period. Patients underwent Unified Parkinson's Disease Rating Scale (UPDRS) evaluations and completed a Beck's Depression Inventory (BDI) and a Sexual Health Inventory‐M version (SHI‐M) at baseline and after 8 weeks. There was statistically significant improvement in total SHI‐M scores (23.8 ± 2.0 vs 16.6 ± 2.8; p = 0.01), overall sexual satisfaction (p = 0.03), satisfaction with sexual desire (p = 0.04), ability to achieve erection (p = 0.02), ability to maintain erection (p = 0.03), and ability to reach orgasm (p = 0.04) with use of sildenafil citrate. UPDRS and BDI scores were not significantly changed. Side effects included headache in one patient during three sexual encounters. In this open‐label study, sildenafil citrate significantly improved sexual function in men with PD and erectile dysfunction.

Url:

https://api.istex.fr/document/3DECA42D5307E6BAA4476E1058D97F6523C1220B/fulltext/pdf

DOI: 10.1002/1531-8257(200003)15:2<305::AID-MDS1015>3.0.CO;2-W

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
</author>
<author><name sortKey="Helal, Mohammed" sort="Helal, Mohammed" uniqKey="Helal M" first="Mohammed" last="Helal">Mohammed Helal</name>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3DECA42D5307E6BAA4476E1058D97F6523C1220B</idno>
<date when="2000" year="2000">2000</date>
<idno type="doi">10.1002/1531-8257(200003)15:2<305::AID-MDS1015>3.0.CO;2-W</idno>
<idno type="url">https://api.istex.fr/document/3DECA42D5307E6BAA4476E1058D97F6523C1220B/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002D54</idno>
<idno type="wicri:Area/Istex/Curation">002D54</idno>
<idno type="wicri:Area/Istex/Checkpoint">003163</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Zesiewicz T:sildenafil:citrate:viagra</idno>
<idno type="wicri:Area/Main/Merge">007260</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:00-0177310</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C44</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000077</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002B17</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Zesiewicz T:sildenafil:citrate:viagra</idno>
<idno type="wicri:Area/Main/Merge">007509</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10752581</idno>
<idno type="wicri:Area/PubMed/Corpus">004021</idno>
<idno type="wicri:Area/PubMed/Curation">004021</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003E76</idno>
<idno type="wicri:Area/Ncbi/Merge">000230</idno>
<idno type="wicri:Area/Ncbi/Curation">000230</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000230</idno>
<idno type="wicri:doubleKey">0885-3185:2000:Zesiewicz T:sildenafil:citrate:viagra</idno>
<idno type="wicri:Area/Main/Merge">007019</idno>
<idno type="wicri:Area/Main/Curation">004963</idno>
<idno type="wicri:Area/Main/Exploration">004963</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease</title>
<author><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Helal, Mohammed" sort="Helal, Mohammed" uniqKey="Helal M" first="Mohammed" last="Helal">Mohammed Helal</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Surgery, Division of Urology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
<settlement type="city">Tampa</settlement>
</placeName>
<orgName type="university">Université de Floride du Sud</orgName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2000-03">2000-03</date>
<biblScope unit="vol">15</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="305">305</biblScope>
<biblScope unit="page" to="308">308</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">3DECA42D5307E6BAA4476E1058D97F6523C1220B</idno>
<idno type="DOI">10.1002/1531-8257(200003)15:2<305::AID-MDS1015>3.0.CO;2-W</idno>
<idno type="ArticleID">MDS1015</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Chemotherapy</term>
<term>Complication</term>
<term>Dose-Response Relationship, Drug</term>
<term>Erectile Dysfunction (drug therapy)</term>
<term>Erectile dysfunction</term>
<term>Humans</term>
<term>Impotence</term>
<term>Libido (drug effects)</term>
<term>Male</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Penile Erection (drug effects)</term>
<term>Phosphodiesterase Inhibitors (administration & dosage)</term>
<term>Phosphodiesterase Inhibitors (adverse effects)</term>
<term>Pilot Projects</term>
<term>Piperazines (administration & dosage)</term>
<term>Piperazines (adverse effects)</term>
<term>Purines</term>
<term>Sexual function</term>
<term>Sildenafil</term>
<term>Sildenafil citrate</term>
<term>Sulfones</term>
<term>Toxicity</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>Viagra</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Phosphodiesterase Inhibitors</term>
<term>Piperazines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Phosphodiesterase Inhibitors</term>
<term>Piperazines</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Libido</term>
<term>Neurologic Examination</term>
<term>Penile Erection</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Erectile Dysfunction</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Humans</term>
<term>Male</term>
<term>Pilot Projects</term>
<term>Purines</term>
<term>Sulfones</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Adulte</term>
<term>Chimiothérapie</term>
<term>Complication</term>
<term>Fonction sexuelle</term>
<term>Impuissance</term>
<term>Mâle</term>
<term>Parkinson maladie</term>
<term>Sildénafil</term>
<term>Toxicité</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Sildenafil citrate (Viagra) is a phosphodiesterase type V inhibitor used to treat erectile dysfunction. Ten men with idiopathic Parkinson's disease (PD) and erectile dysfunction were prescribed 50–100 mg sildenafil citrate to use in eight sexual encounters over a 2‐month period. Patients underwent Unified Parkinson's Disease Rating Scale (UPDRS) evaluations and completed a Beck's Depression Inventory (BDI) and a Sexual Health Inventory‐M version (SHI‐M) at baseline and after 8 weeks. There was statistically significant improvement in total SHI‐M scores (23.8 ± 2.0 vs 16.6 ± 2.8; p = 0.01), overall sexual satisfaction (p = 0.03), satisfaction with sexual desire (p = 0.04), ability to achieve erection (p = 0.02), ability to maintain erection (p = 0.03), and ability to reach orgasm (p = 0.04) with use of sildenafil citrate. UPDRS and BDI scores were not significantly changed. Side effects included headache in one patient during three sexual encounters. In this open‐label study, sildenafil citrate significantly improved sexual function in men with PD and erectile dysfunction.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Floride</li>
</region>
<settlement><li>Tampa</li>
</settlement>
<orgName><li>Université de Floride du Sud</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Floride"><name sortKey="Zesiewicz, Theresa A" sort="Zesiewicz, Theresa A" uniqKey="Zesiewicz T" first="Theresa A." last="Zesiewicz">Theresa A. Zesiewicz</name>
</region>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<name sortKey="Helal, Mohammed" sort="Helal, Mohammed" uniqKey="Helal M" first="Mohammed" last="Helal">Mohammed Helal</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004963 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004963 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:3DECA42D5307E6BAA4476E1058D97F6523C1220B
   |texte=   Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease

Sildenafil citrate (viagra) for the treatment of erectile dysfunction in men with Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.